Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2005

View Archived Issues

GTx receives response on SPA for Acapodene for prevention of prostate cancer

Novavax and Wave Biotech to collaborate on production processes

Quarterly activities at Medivir

In vivo efficacy of novel p38alpha MAP kinase inhibitors from BMS

A-761: Novel MCHR1 antagonist with in vivo efficacy and cardiovascular safety

Novel selective adenosine A2A receptor antagonist with anticataleptic activity in vivo

Adjuvant trastuzumab increases survival in early-stage breast cancer

Trans NV-04 reported to reduce cardiovascular risk in overweight subjects

Promising effects of MC-4232 in patients with diabetic hypertension

Phase II data on the benefits of once-daily SPD-476 in ulcerative colitis

Rosiglitazone improves treatment satisfaction in elderly patients with type 2 diabetes

LEO Pharma and Warner Chilcott expand U.S. dermatology cooperation

Myozyme studied for late-onset Pompe disease

Cyclacel and Genzyme sign agreement for CDK inhibitors for renal disease

Huntsman Cancer Institute funded to study Curacyte's PHP

Keppra meets primary endpoint in phase III monotherapy epilepsy study

Dendreon plans Provenge BLA filing

Aplaviroc studies in treatment-naive HIV patients halted over liver toxicity

Macugen recommended for approval in Europe

New therapeutics for cancer disclosed in recent patents

Adartrel receives positive opinion in Europe for restless legs syndrome

Shionogi launches antibiotic Finibax in Japan

Novel immunomodulating agents revealed in patents

Once-monthly Bonviva approved in E.U. for postmenopausal osteoporosis

Clinical evidence supports the use of duloxetine for DPNP

Pranlukast induces neuroprotective effects in a model of cerebral ischemia

New data on the effects of DiaPep277 in patients with type 1 diabetes

Update on the effects of rubitecan in advanced NSCLC

Final phase I data on OGX-011 in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...